Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer

Targeting MCL-1 in hematologic malignancies: Rationale and progress

(2020) AndrewH. Wei et al.   BLOOD REVIEWS

A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway

(2020) Yue-Li Sun et al.   BMC CANCER

Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-XL and MCL-1 leads to rapid induction of intrinsic apoptosis

(2020) Sarah Kehr et al.   CANCER LETTERS

Inhibition of BCL2 family members increases the efficacy of copper chelation in BRAFV600E-driven melanoma

(2020) Ye-Jin Kim et al.   CANCER RESEARCH

Molecular Determinants for the Activation/Inhibition of Bak Protein by BH3 Peptides

(2020) Guillem Vila-Julià et al.   Journal of Chemical Information and Modeling

Venetoclax in acute myeloid leukemia – current and future directions

(2020) Curtis Lachowiez et al.   LEUKEMIA & LYMPHOMA

The apoptosis inhibitor Bcl-xL controls breast cancer cell migration through mitochondria-dependent reactive oxygen species production

(2020) Margaux Bessou et al.   ONCOGENE

Cell Death Pathways in Lymphoid Malignancies

(2020) Luke Fletcher et al.   Current Oncology Reports

microRNA-378a-5p iS a novel positive regulator of melanoma progression

(2020) Maria Grazia Tupone et al.   Oncogenesis

Structure‐based design, synthesis, and evaluation of Bcl‐2/Mcl‐1 dual inhibitors

(2020) Junjie Zhu et al.   ARCHIV DER PHARMAZIE

Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor positive breast cancer

(2020) James R Whittle et al.   CLINICAL CANCER RESEARCH

Co‐targeting bromodomain and extra‐terminal proteins and MCL1 induces synergistic cell death in melanoma

(2020) Hsin‐Yi Tseng et al.   INTERNATIONAL JOURNAL OF CANCER

Noncanonical Cell Fate Regulation by Bcl-2 Proteins

(2020) Stephen Jun Fei Chong et al.   TRENDS IN CELL BIOLOGY

Melanoma-specific bcl-2 promotes a protumoral M2-like phenotype by tumor-associated macrophages

(2020) Marta Di Martile et al.   Journal for ImmunoTherapy of Cancer

Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies

(2020) Maxime Jullien et al.   Cells

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors

(2019) Xin Yu et al.   PLoS One

BCL-2 family isoforms in apoptosis and cancer

(2019) Chloe F. A. Warren et al.   Cell Death & Disease

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

(2019) Ian W. Flinn et al.   BLOOD

Ibrutinib and Venetoclax for First-Line Treatment of CLL

(2019) Nitin Jain et al.   NEW ENGLAND JOURNAL OF MEDICINE

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

(2019) Erinna F. Lee et al.   Cell Death & Disease

Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer

(2019) Arik Bernard Schulze et al.   Cancers

Bio-Inspired Dual-Selective BCL-2/c-MYC G-Quadruplex Binders: Design, Synthesis, and Anticancer Activity of Drug-like Imidazo[2,1-i]purine Derivatives

(2019) Sveva Pelliccia et al.   JOURNAL OF MEDICINAL CHEMISTRY

De novo design of bioactive protein switches

(2019) Robert A. Langan et al.   NATURE

Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence

(2019) Hubert Fleury et al.   Nature Communications

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

(2019) Richard W. Birkinshaw et al.   Nature Communications

Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands

(2019) Ziqian Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Modulation of the Apoptosis Gene Bcl-x Function Through Alternative Splicing

(2019) Megan Stevens et al.   Frontiers in Genetics

AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells.

(2019) Justin Cidado et al.   CLINICAL CANCER RESEARCH

Elevated expression of mcl-1 inhibits apoptosis and predicts poor prognosis in patients with surgically resected non-small cell lung cancer

(2019) Qiuyuan Wen et al.   Diagnostic Pathology

Activating the Intrinsic Pathway of Apoptosis Using BIM BH3 Peptides Delivered by Peptide Amphiphiles with Endosomal Release

(2019) Mathew R. Schnorenberg et al.   Materials

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

(2019) Sajid Khan et al.   NATURE MEDICINE

A naphthalene diimide G-quadruplex ligand inhibits cell growth and down-regulates BCL-2 expression in an imatinib-resistant gastrointestinal cancer cell line

(2018) Mekala Gunaratnam et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer

(2018) Yunhui Hu et al.   CANCER LETTERS

BCL-x L -selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis

(2018) Sara Fatima Faqar-Uz-Zaman et al.   CANCER LETTERS

Targeting the BCL2 Gene Promoter G-Quadruplex with a New Class of Furopyridazinone-Based Molecules

(2018) Jussara Amato et al.   ChemMedChem

Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A

(2018) Alma Abou Samra et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

B cell lymphoma 2 (Bcl-2) residues essential for Bcl-2's apoptosis-inducing interaction with Nur77/Nor-1 orphan steroid receptors

(2018) Karl L. Banta et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

(2018) John F. Seymour et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition

(2018) Clare E. Weeden et al.   ONCOGENE

MCL-1 is a prognostic indicator and drug target in breast cancer

(2018) Kirsteen J. Campbell et al.   Cell Death & Disease

A concise review of BCL-2 inhibition in acute myeloid leukemia

(2018) Meera Yogarajah et al.   Expert Review of Hematology

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth

(2018) Patrick Casara et al.   Oncotarget

Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin

(2018) Touko Inao et al.   Oncotarget

Targeting Bcl-2-IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones

(2018) Clark W. Distelhorst   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia

(2018) Haley E. Ramsey et al.   Cancer Discovery

Exploiting MCL-1 dependency with combination MEK + MCL-1 inhibitors leads to induction of apoptosis and tumor regression in KRAS mutant non-small cell lung cancer

(2018) Varuna Nangia et al.   Cancer Discovery

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines

(2018) Delphine Merino et al.   CANCER CELL

Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb

(2018) Simona D’Aguanno et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma

(2017) Georg Karpel-Massler et al.   Expert Opinion on Drug Discovery

Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model

(2017) Chiara Gabellini et al.   INTERNATIONAL JOURNAL OF CANCER

APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2/Bcl-xl in HL-60 cells

(2017) Jing Wang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Binding modes of Bcl-2 homology 3 (BH3) peptides with anti-apoptotic protein A1 and redesign of peptide inhibitors: a computational study

(2017) Yantao Chen et al.   JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Pathways and mechanisms of venetoclax resistance

(2017) Prithviraj Bose et al.   LEUKEMIA & LYMPHOMA

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

(2017) Delphine Merino et al.   Science Translational Medicine

BCL-XL overexpression promotes tumor progression-associated properties

(2017) Daniela Trisciuoglio et al.   Cell Death & Disease

Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response

(2017) Ioannis K. Zervantonakis et al.   Nature Communications

Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy

(2017) Akane Inoue-Yamauchi et al.   Nature Communications

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax

(2017) Joel D. Leverson et al.   Cancer Discovery

Chelerythrine down regulates expression of VEGFA, BCL2 and KRAS by arresting G-Quadruplex structures at their promoter regions

(2017) Jagannath Jana et al.   Scientific Reports

Deactivation of Mcl-1 by Dual-Function Small-Molecule Inhibitors Targeting the Bcl-2 Homology 3 Domain and Facilitating Mcl-1 Ubiquitination

(2016) Ting Song et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer

(2016) Vikram B. Wali et al.   CANCER RESEARCH

BH4 domain of Bcl-2 as a novel target for cancer therapy

(2016) Zhiqing Liu et al.   DRUG DISCOVERY TODAY

The deadly landscape of pro-apoptotic BCL-2 proteins in the outer mitochondrial membrane

(2016) Mark P.A. Luna-Vargas et al.   FEBS Journal

Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors

(2016) Taekyu Lee et al.   FEBS LETTERS

MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC

(2016) Jun Ma et al.   GENE

Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer

(2016) Jun Sakakibara-Konishi et al.   International Journal of Clinical Oncology

A New G-Quadruplex with Hairpin Loop Immediately Upstream of the Human BCL2 P1 Promoter Modulates Transcription

(2016) Buket Onel et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

An Autoinhibited Dimeric Form of BAX Regulates the BAX Activation Pathway

(2016) Thomas P. Garner et al.   MOLECULAR CELL

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain

(2016) Gizem Akçay et al.   Nature Chemical Biology

Allosteric inhibition of antiapoptotic MCL-1

(2016) Susan Lee et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Affinity purification-mass spectrometry analysis of bcl-2 interactome identified SLIRP as a novel interacting protein

(2016) D Trisciuoglio et al.   Cell Death & Disease

Bcl-xL promotes metastasis independent of its anti-apoptotic activity

(2016) Soyoung Choi et al.   Nature Communications

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

Allosteric inhibition of antiapoptotic MCL-1

(2016) Susan Lee et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells

(2016) Kan He et al.   Oncotarget

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth

(2016) Jiusheng Deng et al.   Oncotarget

Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer

(2016) Stephanie Berger et al.   eLife

Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy

(2015) Bingshe Han et al.   CANCER CELL

Pancreatic Cancer Combination Therapy Using a BH3 Mimetic and a Synthetic Tetracycline

(2015) Bridget A. Quinn et al.   CANCER RESEARCH

Myeloid cell leukemia-1 regulates the cell growth and predicts prognosis in gastric cancer

(2015) WAN-SIK LEE et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells

(2015) Nabanita Mukherjee et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Potent and Specific Peptide Inhibitors of Human Pro-Survival Protein Bcl-x L

(2015) Sanjib Dutta et al.   JOURNAL OF MOLECULAR BIOLOGY

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

(2015) Y. Xiao et al.   MOLECULAR CANCER THERAPEUTICS

miR-211 and MITF modulation by Bcl-2 protein in melanoma cells

(2015) Teresa De Luca et al.   MOLECULAR CARCINOGENESIS

Targeting novel signaling pathways for resistant acute myeloid leukemia

(2015) Kathleen M. Sakamoto et al.   MOLECULAR GENETICS AND METABOLISM

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

(2015) Steven M Chan et al.   NATURE MEDICINE

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

(2015) Anthony C. Faber et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

Crystal structure of Bax bound to the BH3 peptide of Bim identifies important contacts for interaction

(2015) A Y Robin et al.   Cell Death & Disease

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

(2015) A. N. Hata et al.   Cancer Discovery

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin

(2015) Zuzanna Baranski et al.   Oncotarget

An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo

(2015) Brandon J. Aubrey et al.   Cell Reports

Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation

(2015) Ulrike Keitel et al.   Oncotarget

Sabutoclax, a Mcl-1 Antagonist, Inhibits Tumorigenesis in Transgenic Mouse and Human Xenograft Models of Prostate Cancer

(2015) Roger S. Jackson et al.   NEOPLASIA

Removal of the BH4 Domain from Bcl-2 Protein Triggers an Autophagic Process that Impairs Tumor Growth

(2015) Daniela Trisciuoglio et al.   NEOPLASIA

Pro-apoptotic meiogynin A derivatives that target Bcl-xL and Mcl-1

(2014) Sandy Desrat et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Expression of pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins in human retinoblastoma

(2014) Lata Singh et al.   CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts

(2014) S. Suryani et al.   CLINICAL CANCER RESEARCH

Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low–normal serum lactate dehydrogenase

(2014) Agop Y. Bedikian et al.   MELANOMA RESEARCH

Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance

(2014) M N Serasinghe et al.   ONCOGENE

Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts

(2014) Fariba Némati et al.   PLoS One

BM-1197: A Novel and Specific Bcl-2/Bcl-xL Inhibitor Inducing Complete and Long-Lasting Tumor Regression In Vivo

(2014) Longchuan Bai et al.   PLoS One

Induction of Bcl-xL-Specific Cytotoxic T Lymphocytes in Mice

(2014) H. L. Larsen et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells

(2014) Lijun Ye et al.   TUMOR BIOLOGY

Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer

(2014) Y Loriot et al.   Cell Death & Disease

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

(2014) Zhi-Fu Tao et al.   ACS Medicinal Chemistry Letters

The Expression of Bcl-2 and BID in Gastric Cancer Cells

(2014) Mariusz Gryko et al.   Journal of Immunology Research

AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia

(2013) Aneel Paulus et al.   BRITISH JOURNAL OF HAEMATOLOGY

Anti-apoptotic proteins on guard of melanoma cell survival

(2013) Mariusz L. Hartman et al.   CANCER LETTERS

BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition

(2013) Chiara Gabellini et al.   CARCINOGENESIS

Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure

(2013) R. L. Thomas et al.   GENES & DEVELOPMENT

Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction

(2013) X. Wang et al.   GENES & DEVELOPMENT

Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity after radioembolization with yttrium-90 resin microspheres

(2013) Elisa Melucci et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

A ruthenium(II) complex capable of inducing and stabilizing bcl-2 G-quadruplex formation as a potential cancer inhibitor

(2013) Jingnan Zhang et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo

(2013) F. Abulwerdi et al.   MOLECULAR CANCER THERAPEUTICS

Structure-guided design of a selective BCL-XL inhibitor

(2013) Guillaume Lessene et al.   Nature Chemical Biology

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Apoptosome Structure, Assembly, and Procaspase Activation

(2013) Shujun Yuan et al.   STRUCTURE

The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches

(2013) Orsola Vitagliano et al.   Expert Review of Hematology

mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1

(2013) A. C. Faber et al.   Cancer Discovery

Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial

(2012) Patrick A. Ott et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The secrets of the Bcl-2 family

(2012) A J García-Sáez   CELL DEATH AND DIFFERENTIATION

Structure-Based Design of Potent Bcl-2/Bcl-xL Inhibitors with Strong in Vivo Antitumor Activity

(2012) Haibin Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

(2011) S. M. Schoenwaelder et al.   BLOOD

Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells

(2011) D Trisciuoglio et al.   CELL DEATH AND DIFFERENTIATION

Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between “triple-negative” and non–“triple-negative” tumors

(2011) Kareem Tawfik et al.   HUMAN PATHOLOGY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

N-Cyclic Bay-Substituted Perylene G-Quadruplex Ligands Have Selective Antiproliferative Effects on Cancer Cells and Induce Telomere Damage

(2011) Valentina Casagrande et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Phase I Trial of Oblimersen Sodium in Combination With Cisplatin and 5-Fluorouracil in Patients With Advanced Esophageal, Gastroesophageal Junction, and Gastric Carcinoma

(2010) Rachel Raab et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

TheBCL-25′ Untranslated Region Contains an RNA G-Quadruplex-Forming Motif That Modulates Protein Expression

(2010) Ramla Shahid et al.   BIOCHEMISTRY

Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies

(2010) Peter S. Galatin et al.   INVESTIGATIONAL NEW DRUGS

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Mitochondria and cell death: outer membrane permeabilization and beyond

(2010) Stephen W. G. Tait et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Bcl-2 Regulates HIF-1α Protein Stabilization in Hypoxic Melanoma Cells via the Molecular Chaperone HSP90

(2010) Daniela Trisciuoglio et al.   PLoS One

Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing

(2009) Yao Zhao et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells

(2009) Dae Kim et al.   Molecular Cancer

Cell Death

(2009) Richard S. Hotchkiss et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

(2008) F. T. Awan et al.   BLOOD

A Short Nur77-Derived Peptide Converts Bcl-2 from a Protector to a Killer

(2008) Siva Kumar Kolluri et al.   CANCER CELL

Mcl-1 is a potential therapeutic target in multiple types of cancer

(2008) C. Akgul   CELLULAR AND MOLECULAR LIFE SCIENCES

Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma

(2008) Chiara Gabellini et al.   JOURNAL OF NEUROCHEMISTRY

Significance of Bcl-xL in human colon carcinoma

(2008) You-Li Zhang et al.   WORLD JOURNAL OF GASTROENTEROLOGY